Integrated Screening & Validation Platform for AI-Driven Drug Development
AI is transforming drug discovery by enabling the rapid generation of vast numbers of candidate sequences. ACROBiosystems (ACRO) AIDD-Ready is an integrated screening and validation platform designed to translate AI-generated sequences into experimentally validated candidates.
Built on a core product portfolio and the CHO-Direct™ service platform, AIDD-Ready supports AI-designed antibodies from virtual design through preclinical development. Standardized, scalable wet-lab workflows integrate antibody expression, screening, functional validation, and in-depth characterization, generating high-quality experimental data to drive model optimization and candidate selection. By closing the loop between AI design and experimental validation, AIDD-Ready accelerates the translation of in silico sequences into active candidates and unlocks the full potential of AI-driven innovation.
Faced with the large number of antibody candidates generated by AI, efficient screening requires reliable, ready-to-use antigens. ACRO offers recombinant proteins covering a broad range of drug targets. Validated by BLI/SPR affinity testing, these proteins can be used directly for binding and affinity screening of antibody candidates, enabling rapid Hit identification while reducing time spent on protein preparation and assay optimization—well suited to the high-throughput, fast-paced nature of AI-driven drug development.
BLI/SPR affinity testing provides real binding data to confirm protein activity, ensuring reliable performance in AI-driven antibody screening.
A broad portfolio of drug targets across disease areas provides diverse antigen resources for large-scale screening of AI-generated antibody candidates.
Pre-validated proteins minimize protein preparation and assay optimization, enabling direct BLI/SPR screening and faster identification of promising Hits.
CHO-Direct™ is purpose-built for AI-driven antibody pipelines, connecting the full workflow from AI-powered design → Stage 1: high-throughput screening → Stage 2: antibody expression & purification → Stage 3: in-depth characterization → AI model iteration / preclinical development. It provides a standardized, reproducible, and iterative wet-lab framework to efficiently advance AI-designed antibodies from virtual design to preclinical development.
AIDD-Ready also includes a cell-free expression (CFS) platform for rapid production of small proteins such as VHHs and mini-proteins. With fast turnaround, CFS complements CHO-Direct™ to support wet-lab validation across diverse AI-designed molecules.
High-throughput validation of AI-generated antibody sequences enables rapid identification of positive candidates and efficient elimination of non-performing sequences. This reduces downstream validation costs while generating the first round of experimental data to drive AI model iteration.
Standard Workflow
Automated Report Delivered in as Fast as 4 Days AI Antibody Sequence Receipt & Analysis
Gene Synthesis & Construct Generation
CHO Cell Transfection & Expression
Supernatant Harvest & Testing
Automated Report Delivery
Core ServicesAssess antibody expression to rapidly identify low-expressing or abnormal sequences
High-throughput affinity analysis with automated reporting for efficient candidate ranking
Confirm binding specificity and minimize false positives
Cell-based binding screening for membrane protein targets
Characterize antibody epitopes
TR-FRET/ELISA blocking and binding assays for early assessment of candidate activity
Core Service Advantages96-well high-throughput parallel screening rapidly eliminates low-expression and low-activity sequences, focusing efforts on high-potential candidates
Rapidly generate multidimensional data on expression, binding activity, and kinetics, providing timely feedback for AI model iteration
Eliminate the need to build an in-house high-throughput expression platform, reducing early-stage R&D costs
AmMag™ Quatro 1300 Automated Antibody Purification System
Hamilton Microlab® STAR Automated Liquid Handling Workstation
Octet® RH96 96-Channel High-Throughput System
Biacore™ 8K Biomolecular Interaction Analysis System
BMG LABTECH Multimode Microplate Reader
Uncle Biologics Stability Screening Platform
Starting from AI-designed antibody sequences, CHO-Direct™ provides one-stop wet-lab validation covering high-throughput expression, functional activity, and developability assessment.



